Phase 3 trial shows 26% PFS improvement; call options volume jumps 2,599%

ABBVABBV•124d ago

AbbVie and Genmab’s Phase 3 EPCORE DLBCL-1 trial showed epcoritamab reduced risk of progression or death by 26% (HR 0.74; 95% CI 0.60–0.92) versus standard chemoimmunotherapy in 483 relapsed/refractory DLBCL patients. Concurrently, ABBV call option volume spiked 2,599%, signaling heavy bullish speculation ahead of regulatory discussions.

Sources

FMGP

Phase 3 trial shows 26% PFS improvement; call options volume jumps 2,599%

Related News

AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers

Nordson Posts Record Q2 $741M Sales, Raises Full-Year Sales to $2.93-$3.01B

Live Ventures Inc Reports 14.8% Retail Growth, 3.8% Revenue Decline, $2.4M Loss

Silvercorp Secures 30-Year License Extension, Pays $60M for Tulkubash/Kyzyltash JV

Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board

Sources

Ask about ABBV

Phase 3 trial shows 26% PFS improvement; call options volume jumps 2,599%

Related News

AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers

Nordson Posts Record Q2 $741M Sales, Raises Full-Year Sales to $2.93-$3.01B

Live Ventures Inc Reports 14.8% Retail Growth, 3.8% Revenue Decline, $2.4M Loss

Silvercorp Secures 30-Year License Extension, Pays $60M for Tulkubash/Kyzyltash JV

Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board

Sources